CSPC PHARMA (01093) Rises Over 3% in Late Trading as Second Marketing Authorization Application for Semaglutide Injection Accepted

Stock News12-10

CSPC PHARMA (01093) surged over 3% in late trading, closing up 2.92% at HK$7.75 with a turnover of HK$515 million. On December 8, the company announced that its subsidiary, CSPC Baike (Shandong) Biopharmaceutical, had its second marketing authorization application for semaglutide injection accepted by China's National Medical Products Administration (NMPA).

The latest application targets long-term weight management in overweight/obese adults alongside dietary control and increased physical activity. Previously, the NMPA accepted an application in August 2025 for the treatment of type 2 diabetes in adults.

The submission is supported by a Phase III clinical trial demonstrating significant weight and waist circumference reduction, along with improved blood glucose, lipid, and liver enzyme levels in non-diabetic obese adults. Compared to Novo Nordisk's semaglutide, CSPC's product showed highly consistent efficacy, similar safety profiles, better tolerability, and slightly lower adverse event rates.

Given its advantages in efficacy, safety, and formulation, the drug holds strong clinical potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133789021?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 15:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133789021","market":"nz","top_or_hot":-1,"title":"CSPC PHARMA (01093) Rises Over 3% in Late Trading as Second Marketing Authorization Application for Semaglutide Injection Accepted","media":"Stock News","content":"<p>CSPC PHARMA (01093) surged over 3% in late trading, closing up 2.92% at HK$7.75 with a turnover of HK$515 million. On December 8, the company announced that its subsidiary, CSPC Baike (Shandong) Biopharmaceutical, had its second marketing authorization application for semaglutide injection accepted by China's National Medical Products Administration (NMPA).</p>\n<p>The latest application targets long-term weight management in overweight/obese adults alongside dietary control and increased physical activity. Previously, the NMPA accepted an application in August 2025 for the treatment of type 2 diabetes in adults.</p>\n<p>The submission is supported by a Phase III clinical trial demonstrating significant weight and waist circumference reduction, along with improved blood glucose, lipid, and liver enzyme levels in non-diabetic obese adults. Compared to Novo Nordisk's semaglutide, CSPC's product showed highly consistent efficacy, similar safety profiles, better tolerability, and slightly lower adverse event rates.</p>\n<p>Given its advantages in efficacy, safety, and formulation, the drug holds strong clinical potential.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC PHARMA (01093) Rises Over 3% in Late Trading as Second Marketing Authorization Application for Semaglutide Injection Accepted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC PHARMA (01093) Rises Over 3% in Late Trading as Second Marketing Authorization Application for Semaglutide Injection Accepted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-10 15:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC PHARMA (01093) surged over 3% in late trading, closing up 2.92% at HK$7.75 with a turnover of HK$515 million. On December 8, the company announced that its subsidiary, CSPC Baike (Shandong) Biopharmaceutical, had its second marketing authorization application for semaglutide injection accepted by China's National Medical Products Administration (NMPA).</p>\n<p>The latest application targets long-term weight management in overweight/obese adults alongside dietary control and increased physical activity. Previously, the NMPA accepted an application in August 2025 for the treatment of type 2 diabetes in adults.</p>\n<p>The submission is supported by a Phase III clinical trial demonstrating significant weight and waist circumference reduction, along with improved blood glucose, lipid, and liver enzyme levels in non-diabetic obese adults. Compared to Novo Nordisk's semaglutide, CSPC's product showed highly consistent efficacy, similar safety profiles, better tolerability, and slightly lower adverse event rates.</p>\n<p>Given its advantages in efficacy, safety, and formulation, the drug holds strong clinical potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004220.SGD","symbol_name":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","start_time":0,"source_url":"","article_id":"1133789021","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133789021","pubTimestamp":1765351458,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSPC PHARMA (01093) surged over 3% in late trading, closing up 2.92% at HK$7.75 with a turnover of HK$515 million. On December 8, the company announced that its subsidiary, CSPC Baike (Shandong)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","BK1191":"制药","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","01093":"石药集团","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1515":"抗疫概念","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1521":"挪威政府全球养老基金持仓","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC"},"translate_title":"石药制药(01093)尾盘涨超3%司美格鲁肽注射液第二次上市许可申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC PHARMA (01093) surged over 3% in late trading, closing up 2.92% at HK$7.75 with a turnover of HK$515 million. On December 8, the company announced that its subsidiary, CSPC Baike (Shandong) Biopharmaceutical, had its second marketing authorization application for semaglutide injection accepted by China's National Medical Products Administration (NMPA).\nThe latest application targets long-term weight management in overweight/obese adults alongside dietary control and increased physical activity. Previously, the NMPA accepted an application in August 2025 for the treatment of type 2 diabetes in adults.\nThe submission is supported by a Phase III clinical trial demonstrating significant weight and waist circumference reduction, along with improved blood glucose, lipid, and liver enzyme levels in non-diabetic obese adults. Compared to Novo Nordisk's semaglutide, CSPC's product showed highly consistent efficacy, similar safety profiles, better tolerability, and slightly lower adverse event rates.\nGiven its advantages in efficacy, safety, and formulation, the drug holds strong clinical potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133789021","isCrawlerRequest":true}